Avacta has announced its second partnership to exploit the recently generated Affimer binders to the SARS-COV-2 virus in a high-throughput COVID-19 antigen test.
This follows the Group’s stated intention to partner its SARS-COV-2 spike protein Affimer reagents with several select companies in order to support antigen test development on multiple diagnostic platforms.
This is expected to contribute most effectively to the urgent need for rapid antigen tests to diagnose this coronavirus infection, such that it can be mass-produced for a rapid, professional screening of large populations and, potentially for self-testing by consumers themselves.
This is crucial to limiting and tracking the spread of this disease. The two companies are aiming to have a BAMS™ test ready for clinical validation, regulatory approval and manufacturing in June.
Although the full terms of business have not been disclosed, Avacta will receive a royalty on the sales of Adeptrix test kits. As such this represents another important step forward, not only in terms of development of a reputation-building, high-profile new product of global significance, but also in terms of Avacta maximising the near and longer-term commercial opportunities for its platform.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Avacta Group plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned